These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 10353296)

  • 1. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs.
    Palatini P
    Drugs; 1999 May; 57(5):713-24. PubMed ID: 10353296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated heart rate as a predictor of increased cardiovascular morbidity.
    Palatini P
    J Hypertens Suppl; 1999 Aug; 17(3):S3-10. PubMed ID: 10489092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of heart rate as a risk factor in hypertension.
    Palatini P; Julius S
    Curr Hypertens Rep; 1999 Jun; 1(3):219-24. PubMed ID: 10981069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of tachycardia with morbidity and mortality: pathophysiological considerations.
    Palatini P; Julius S
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S19-27. PubMed ID: 9321736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy.
    Palatini P; Benetos A; Julius S
    Drugs; 2006; 66(2):133-44. PubMed ID: 16451089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The physiological determinants and risk correlations of elevated heart rate.
    Palatini P; Julius S
    Am J Hypertens; 1999 Jan; 12(1 Pt 2):3S-8S. PubMed ID: 10077413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment of patients with hypertension: therapeutic implications of INSIGHT.
    Taddei S; Ghiadoni L; Salvetti A
    Drugs; 2003; 63(14):1435-44. PubMed ID: 12834362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an L- and N-type calcium channel blocker in hypertensive patients with neurovascular compression of the rostral ventrolateral medulla.
    Aota Y; Morimoto S; Sakuma T; Morita T; Jo F; Takahashi N; Maehara M; Ikeda K; Sawada S; Iwasaka T
    Hypertens Res; 2009 Aug; 32(8):700-5. PubMed ID: 19521420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated heart rate: a major risk factor for cardiovascular disease.
    Palatini P; Julius S
    Clin Exp Hypertens; 2004; 26(7-8):637-44. PubMed ID: 15702618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.
    Thomas GN; Chan P; Tomlinson B
    Drugs Aging; 2006; 23(2):131-55. PubMed ID: 16536636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated heart rate in cardiovascular diseases: a target for treatment?
    Palatini P
    Prog Cardiovasc Dis; 2009; 52(1):46-60. PubMed ID: 19615493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of hypertension in atherosclerosis and cardiovascular disease.
    Hollander W
    Am J Cardiol; 1976 Nov; 38(6):786-800. PubMed ID: 136891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resting heart rate in cardiovascular disease.
    Fox K; Borer JS; Camm AJ; Danchin N; Ferrari R; Lopez Sendon JL; Steg PG; Tardif JC; Tavazzi L; Tendera M;
    J Am Coll Cardiol; 2007 Aug; 50(9):823-30. PubMed ID: 17719466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sympathetic overactivity in hypertension: a risk factor for cardiovascular disease.
    Palatini P
    Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S3-9. PubMed ID: 11580882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart rate as a cardiovascular risk factor: do women differ from men?
    Palatini P
    Ann Med; 2001 May; 33(4):213-21. PubMed ID: 11405541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC
    Br Med Bull; 2009; 90():71-84. PubMed ID: 19474056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension.
    Bangalore S; Sawhney S; Messerli FH
    J Am Coll Cardiol; 2008 Oct; 52(18):1482-9. PubMed ID: 19017516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.